Menu

Lipitor Patent Expires

The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.

Nov 30, 2011
Cristina Luiggi

DREAMSTIME, KATERYNA PORTOKHOVA

Pfizer’s monopoly over the blockbuster cholesterol-reducing molecule atorvastatin, trade name Lipitor, ends today (November 30) with the expiration of the patent that has brought the company over $100 billion since the drug was introduced in 1997. While the introduction of generic alternatives into the market may pose a relief for consumer pockets, the expiration of patents for Lipitor and other drugs in the next three years may result in a loss of about $95 billion for big drug companies, Nature reported.

Atorvastatin was first synthesized in 1985 by Bruce D. Roth, a chemist working at Parke-Davis Warner-Lambert Company (now Pfizer). Modeled after naturally occurring compounds known as statins, atorvastatin reduces blood cholesterol by inhibiting a key liver enzyme involved in the production of cholesterol. When Lipitor splashed into the market in 1997, it was celebrated as a marked improvement over available drugs due to its high efficiency and few side effects.

But the past decade has not boded well for pharmaceutical companies, as investors have come to realize that success stories such as Lipitor’s are more the exception than the norm. As a result, big companies such as Pfizer have drastically reduced their research and development budgets, and many are shying away from possible blockbusters and turning toward more niche drugs, according to Nature.

Generic Lipitor, produced by New Jersey-based Watson Pharmaceuticals Inc., will be available as early as December 5, with other companies following suit pending FDA clearance, Bloomberg reported.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.